QM · rank #6 · 2026-09-08
LQDA
NASDAQ · $6.14B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +341.17% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +131.8% |
| Profit margin Net profit margin, trailing 12 months. | +30.7% |
| Market cap (USD) Size filter: > $500M required. | $6.14B |
| Anchor (recent) Close on 2026-08-07 | $90.22 |
| Anchor (far) Close on 2025-08-08 | $20.45 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a rare cardiopulmonary specialty pharma company commercializing YUTREPIA, an inhaled dry-powder treprostinil for PAH and PH-ILD, which drove $170.4M in Q2 2026 net product sales—up 31% sequentially—and delivered its fourth consecutive profitable quarter.
Rationale
The quality_momentum signal is directly reinforced by LQDA's explosive revenue ramp (from ~$8.8M in Q2 2025 to $170.4M in Q2 2026), a 30%+ profit margin, and an ROE above 1.3x, all consistent with a single-product franchise hitting commercial escape velocity in a high-value rare disease niche.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, label restriction, or a larger cardiopulmonary player (e.g., United Therapeutics) successfully launching a competing dry-powder treprostinil or superior delivery mechanism could collapse the revenue base with no offset.
- 2Reimbursement and payer pressure on a high-cost specialty therapy could compress net pricing and slow prescriber adoption, particularly as YUTREPIA scales beyond early-adopter PAH centers into broader community pulmonology practice.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.